Literature DB >> 26512762

HPV vaccines: Translating immunogenicity into efficacy.

Taylor B Turner1, Warner K Huh1.   

Abstract

Currently available human papillomavirus (HPV) vaccines are very successful at preventing persistent HPV infection and premalignant cervical lesions. In part due to the unique aspects of HPV immunogenicity and high levels of efficacy no immune correlate has been identified for HPV vaccination. Serum neutralizing antibodies are used to measure vaccine response, but their role as a correlate has not been verified, and this theory fails to explain the prevention of HPV related non-mucosal lesions. Identifying a true correlate would aid in future work in this area but will be difficult in the setting of a highly efficacious vaccine.

Entities:  

Keywords:  Human papilloma virus vaccine; immune correlate

Mesh：

Substances：

Year:  2015        PMID： 26512762      PMCID： PMC4964637          DOI： 10.1080/21645515.2015.1103936

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  23 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines.

Authors:  I M Onorato; J F Modlin; A M McBean; M L Thoms; G A Losonsky; R H Bernier
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

Review 3.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

4.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.

Authors:  R B Belshe; W C Gruber; P M Mendelman; H B Mehta; K Mahmood; K Reisinger; J Treanor; K Zangwill; F G Hayden; D I Bernstein; K Kotloff; J King; P A Piedra; S L Block; L Yan; M Wolff
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

5.  Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.

Authors:  Cecilia M Roteli-Martins; Paulo Naud; Paola De Borba; Julio C Teixeira; Newton S De Carvalho; Toufik Zahaf; Nervo Sanchez; Brecht Geeraerts; Dominique Descamps
Journal:  Hum Vaccin Immunother       Date:  2012-02-13       Impact factor: 3.452

6.  Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer.

Authors:  I Jochmus-Kudielka; A Schneider; R Braun; R Kimmig; U Koldovsky; K E Schneweis; K Seedorf; L Gissmann
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

7.  Skin cancer and warts in immunosuppressed renal transplant recipients.

Authors:  I M Leigh; M T Glover
Journal:  Recent Results Cancer Res       Date:  1995

8.  Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.

Authors:  B Romanowski; P Colares de Borba; P S Naud; C M Roteli-Martins; N S De Carvalho; J C Teixeira; F Aoki; B Ramjattan; R M Shier; R Somani; S Barbier; M M Blatter; C Chambers; D Ferris; S A Gall; F A Guerra; D M Harper; J A Hedrick; D C Henry; A P Korn; R Kroll; A-B Moscicki; W D Rosenfeld; B J Sullivan; C S Thoming; S K Tyring; C M Wheeler; G Dubin; A Schuind; T Zahaf; Mary Greenacre; An Sgriobhadair
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

9.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

10.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103
View more
  9 in total

Review 1.  Vaginal delivery of vaccines.

Authors:  Hannah M VanBenschoten; Kim A Woodrow
Journal:  Adv Drug Deliv Rev       Date:  2021-09-01       Impact factor: 15.470

2.  Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations.

Authors:  Marc H Jansen; Christien Rondaan; Geertje Legger; Kirsten Minden; Yosef Uziel; Nataša Toplak; Despoina Maritsi; Mirjam van den Berg; Guy Berbers; Patricia Bruijning; Yona Egert; Christophe Normand; Marc Bijl; Helen Foster; Isabelle Kone-Paut; Carine Wouters; Angelo Ravelli; Ori Elkayam; Nicolaas M Wulffraat; Marloes W Heijstek
Journal:  Front Pediatr       Date:  2022-07-06       Impact factor: 3.569

3.  A case study and proposal for publishing directed acyclic graphs: The effectiveness of the quadrivalent human papillomavirus vaccine in perinatally HIV Infected girls.

Authors:  Ruby Barnard-Mayers; Hiba Kouser; Jamie A Cohen; Katherine Tassiopoulos; Ellen C Caniglia; Anna-Barbara Moscicki; Nicole G Campos; Michelle R Caunca; George R Seage Seage; Eleanor J Murray
Journal:  J Clin Epidemiol       Date:  2022-01-05       Impact factor: 7.407

Review 4.  An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls.

Authors:  Robine Donken; Johannes A Bogaards; Fiona R M van der Klis; Chris J L M Meijer; Hester E de Melker
Journal:  Hum Vaccin Immunother       Date:  2016-05-12       Impact factor: 3.452

5.  An investigation into the role of chronic Schistosoma mansoni infection on Human Papillomavirus (HPV) vaccine induced protective responses.

Authors:  Vicky Gent; Rebecca Waihenya; Lucy Kamau; Ruth Nyakundi; Peris Ambala; Thomas Kariuki; Lucy Ochola
Journal:  PLoS Negl Trop Dis       Date:  2019-08-26

Review 6.  A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities.

Authors:  Michelle B Shin; Gui Liu; Nelly Mugo; Patricia J Garcia; Darcy W Rao; Cara J Bayer; Linda O Eckert; Leeya F Pinder; Judith N Wasserheit; Ruanne V Barnabas
Journal:  Front Public Health       Date:  2021-07-01

Review 7.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561

8.  Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine.

Authors:  Jade Pattyn; Severien Van Keer; Laura Téblick; Pierre Van Damme; Alex Vorsters
Journal:  Front Immunol       Date:  2020-08-05       Impact factor: 7.561

Review 9.  Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge.

Authors:  J Hoes; H Pasmans; T M Schurink-van 't Klooster; F R M van der Klis; R Donken; J Berkhof; H E de Melker
Journal:  Hum Vaccin Immunother       Date:  2021-05-25       Impact factor: 3.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.